Bincy P. Abraham, M.D., M.S. is the director of the Fondren Inflammatory Bowel Disease Program at the David Underwood Center for Digestive Disorders at Houston Methodist Hospital. Dr. Abraham earned her medical degree from University of Texas Medical Branch, Galveston, TX, where she continued with residency training in internal medicine and fellowship in gastroenterology. During fellowship, she received specialized training in inflammatory bowel disease and earned her degree in Masters of Clinical Investigation. She also completed a National Visiting Fellow Inflammatory Bowel Disease Rotation program through the Crohn’s and Colitis Foundation of America in Cedars Sinai Hospital in Los Angeles. Her particular interest in inflammatory bowel disease includes the transition of adolescent IBD patients from pediatric to adult care as well as women’s issues and pregnancy in IBD. She also directs the Gastroenterology Fellowship program at Houston Methodist.

Houston Methodist Hospital

Houston Methodist is comprised of a leading academic medical center in the Texas Medical Center® and four community hospitals serving the greater Houston area. Each hospital is staffed with committed personnel who exemplify our core values: integrity, compassion, accountability, respect and excellence. Patient safety, quality and service are our highest priorities. Houston Methodist Hospital, the system's flagship, is consistently listed among U.S. News & World Report's best hospitals and we extend that same level of quality care across the system. Other available services include the Houston Methodist Emergency Care Center, Houston Methodist Imaging Center, and Houston Methodist Outpatient Center.

 Community Perspectives: Combining Serology, Genetics, and Inflammation Markers for the Diagnosis of IBD and Differentiation Between CD and UC.

 Natural history of pediatric-onset inflammatory bowel disease: a systematic review.

 Fecal markers: calprotectin and lactoferrin.

 Disability in inflammatory bowel disease.

 Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics.

 Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature.

 Inflammatory bowel disease characteristics in Hispanic children in Texas.

 Intermittent gastric outlet obstruction caused by a prolapsing antral gastric polyp.

 Fine needle aspiration diagnosis of necrotizing eosinophilic abscess clinically mimicking hepatic neoplasia: a case report.

 Clinical significance of inflammatory markers.

 Management of the pregnant IBD patient

 Drug-induced diarrhea.

 Neural stem cells express RET, produce nitric oxide, and survive transplantation in the gastrointestinal tract.

 Functional Dyspepsia Treatment Trial (FDTT)

Functional dyspepsia is a common gastrointestinal disorder. Symptoms can include stomach pain or discomfort, bloating, fullness after eating meals, and nausea. These symptoms often interfere with school and work, and weight loss may occur due to dietary restrictions. The hypothesis of this study was that antidepressant therapy is more effective than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidity. The study also examined if antidepressant therapy reduces disability and improves quality of life in functional dyspepsia.

Enrollment: 292
Study Start Date: October 2006
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure) Ages Eligible for Study: 18 Years to 75 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No